0.8558
price up icon0.58%   0.0042
 
loading
Precedente Chiudi:
$0.86
Aprire:
$0.86
Volume 24 ore:
5,246
Relative Volume:
0.04
Capitalizzazione di mercato:
$12.99M
Reddito:
$500.00K
Utile/perdita netta:
$-19.45M
Rapporto P/E:
-0.4528
EPS:
-1.89
Flusso di cassa netto:
$-18.22M
1 W Prestazione:
-0.80%
1M Prestazione:
-20.64%
6M Prestazione:
-9.80%
1 anno Prestazione:
-36.15%
Intervallo 1D:
Value
$0.855
$0.8996
Intervallo di 1 settimana:
Value
$0.832
$0.9079
Portata 52W:
Value
$0.64
$3.65

Imunon Inc Stock (IMNN) Company Profile

Name
Nome
Imunon Inc
Name
Telefono
(609) 896-9100
Name
Indirizzo
997 LENOX DRIVE, LAWRENCEVILLE
Name
Dipendente
25
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
IMNN's Discussions on Twitter

Confronta IMNN con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
IMNN
Imunon Inc
0.855 12.99M 500.00K -19.45M -18.22M -1.89
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
501.80 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
567.47 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
629.64 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
258.54 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
248.31 24.70B 3.81B -644.79M -669.77M -6.24

Imunon Inc Borsa (IMNN) Ultime notizie

pulisher
Apr 27, 2025

IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates - ADVFN

Apr 27, 2025
pulisher
Apr 23, 2025

Imunon, Inc. (NASDAQ:IMNN) Sees Significant Growth in Short Interest - Defense World

Apr 23, 2025
pulisher
Apr 21, 2025

Imunon announces IMNN-001 abstract accepted for oral presentation at 2025 ASCO - TipRanks

Apr 21, 2025
pulisher
Apr 21, 2025

IMUNON (IMNN) Reveals Promising Survival Data for Advanced Ovari - GuruFocus

Apr 21, 2025
pulisher
Apr 21, 2025

IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting | IMNN Stock News - GuruFocus

Apr 21, 2025
pulisher
Apr 21, 2025

IMUNON, Inc. Announces Presentation of Promising Overall Survival Data from Phase 2 OVATION 2 Study for Advanced Ovarian Cancer and Initiation of Phase 3 Trial Sites for IMNN-001 - Nasdaq

Apr 21, 2025
pulisher
Apr 21, 2025

IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting - GlobeNewswire

Apr 21, 2025
pulisher
Apr 21, 2025

First Effective IL-12 Immunotherapy Shows Survival Benefits in Advanced Ovarian CancerASCO 2025 Preview - Stock Titan

Apr 21, 2025
pulisher
Apr 17, 2025

Imunon (NASDAQ:IMNN) Trading Down 1.9% – Time to Sell? - Defense World

Apr 17, 2025
pulisher
Apr 09, 2025

Celsion Corporation Announces Appointment of Michael H. Tardugno to Executive Chairman of the Board - marketscreener.com

Apr 09, 2025
pulisher
Apr 04, 2025

Imunon (IMNN) Files to Sell 10 Million Shares, Warrants - GuruFocus

Apr 04, 2025
pulisher
Apr 01, 2025

DNA Vaccines Offer a New Path Beyond mRNA Technology - Technology Networks

Apr 01, 2025
pulisher
Apr 01, 2025

Stacy Lindborg, PhD's Profile Page - Technology Networks

Apr 01, 2025
pulisher
Mar 31, 2025

Companies To Watch: Imunon - Life Science Leader

Mar 31, 2025
pulisher
Mar 28, 2025

IMNN: Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer - Smartkarma

Mar 28, 2025
pulisher
Mar 28, 2025

IMNN: Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer… - Zacks Small Cap Research

Mar 28, 2025
pulisher
Mar 28, 2025

Imunon (NASDAQ:IMNN) Earns “Buy” Rating from HC Wainwright - Defense World

Mar 28, 2025
pulisher
Mar 25, 2025

FDA aligns with Imunon’s Phase III trial protocol for ovarian cancer treatment - Yahoo

Mar 25, 2025
pulisher
Mar 25, 2025

Imunon (NASDAQ:IMNN) Receives “Buy” Rating from D. Boral Capital - Defense World

Mar 25, 2025
pulisher
Mar 24, 2025

IMUNON advances to Phase 3 trial in ovarian cancer treatment By Investing.com - Investing.com South Africa

Mar 24, 2025
pulisher
Mar 24, 2025

Imunon finalizes Phase 3 study design with FDA for IMNN-001 - TipRanks

Mar 24, 2025
pulisher
Mar 24, 2025

IMUNON advances to Phase 3 trial in ovarian cancer treatment - Investing.com India

Mar 24, 2025
pulisher
Mar 24, 2025

IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer - GlobeNewswire

Mar 24, 2025
pulisher
Mar 24, 2025

Breakthrough Ovarian Cancer Treatment Shows 46-Month Survival as FDA Clears Phase 3 Trial - Stock Titan

Mar 24, 2025
pulisher
Mar 07, 2025

IMUNON’s IMNN-101 Vaccine Shows Promising Results in Phase 1 Trial, Demonstrates Cross-Reactivity Against COVID Variants - Contagionlive.com

Mar 07, 2025
pulisher
Mar 03, 2025

Imunon, Inc. Earnings Call: Clinical Success Amid Financial Challenges - TipRanks

Mar 03, 2025
pulisher
Mar 02, 2025

Imunon’s (IMNN) “Buy” Rating Reiterated at D. Boral Capital - Defense World

Mar 02, 2025
pulisher
Feb 28, 2025

Imunon’s Strategic Clinical Advancements and Promising Research Drive Buy Rating - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

Imunon, Inc. (NASDAQ:IMNN) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 28, 2025
pulisher
Feb 28, 2025

H.C. Wainwright lifts Imunon stock target to $14 on Phase 3 plans By Investing.com - Investing.com South Africa

Feb 28, 2025
pulisher
Feb 28, 2025

H.C. Wainwright lifts Imunon stock target to $14 on Phase 3 plans - Investing.com

Feb 28, 2025
pulisher
Feb 28, 2025

IMNN: Phase 3 Ovarian Cancer Trial to get Underway in Mar 2025 - Smartkarma

Feb 28, 2025
pulisher
Feb 28, 2025

Imunon Inc (IMNN) Q4 2024 Earnings Call Highlights: Promising Advances Amid Financial Challenges - Yahoo Finance

Feb 28, 2025
pulisher
Feb 28, 2025

IMUNON, Inc. Reports 2024 Financial Results and Advances Clinical Programs - TipRanks

Feb 28, 2025
pulisher
Feb 27, 2025

Earnings call transcript: Imunon Q4 2024 reports improved EPS, stock declines - Investing.com

Feb 27, 2025
pulisher
Feb 27, 2025

Imunon Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 27, 2025
pulisher
Feb 27, 2025

IMUNON Reports 2024 Financial Results and Provides Business Update - TradingView

Feb 27, 2025
pulisher
Feb 27, 2025

IMUNON Reports 2024 Financial Results and Provides Business - GlobeNewswire

Feb 27, 2025
pulisher
Feb 27, 2025

IMUNON's Cancer Immunotherapy Shows 13-Month Survival Benefit in Ovarian Cancer | IMNN Stock News - StockTitan

Feb 27, 2025
pulisher
Feb 27, 2025

Imunon reports immunogenicity and safety data from DNA plasmid vaccine trial - Yahoo Finance

Feb 27, 2025
pulisher
Feb 26, 2025

Imunon announces new analyses of results from Phase 1 trial of IMNN-101 - TipRanks

Feb 26, 2025
pulisher
Feb 26, 2025

IMUNON Announces New Immunogenicity Data from Phase 1 - GlobeNewswire

Feb 26, 2025
pulisher
Feb 26, 2025

Can IMUNON's DNA Vaccine Outperform mRNA COVID Shots? New Clinical Data Reveals Key Advantages - StockTitan

Feb 26, 2025
pulisher
Feb 22, 2025

Imunon (IMNN) Expected to Announce Quarterly Earnings on Thursday - Defense World

Feb 22, 2025
pulisher
Feb 20, 2025

Imunon Inc [IMNN] Shares Jump Approximately 66.98% Over the Year - Knox Daily

Feb 20, 2025
pulisher
Feb 20, 2025

The time has not yet come to remove your chips from the table: Imunon Inc (IMNN) - SETE News

Feb 20, 2025
pulisher
Feb 20, 2025

IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025 - The Manila Times

Feb 20, 2025
pulisher
Feb 20, 2025

IMUNON, Inc. to Announce Full Year 2024 Financial Results on February 27, 2025 - Nasdaq

Feb 20, 2025
pulisher
Feb 20, 2025

New Phase II data confirm promise of Imunon’s IMMN-001 - The Pharma Letter

Feb 20, 2025
pulisher
Feb 20, 2025

IMNNImunon Inc Latest Stock News & Market Updates - Stock Titan

Feb 20, 2025
pulisher
Feb 20, 2025

IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer - GlobeNewswire

Feb 20, 2025

Imunon Inc Azioni (IMNN) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Imunon Inc Azioni (IMNN) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Lindborg Stacy
President and CEO
Aug 15 '24
Buy
0.98
25,000
24,500
264,166
Tardugno Michael H
Executive Chairman of Board
Aug 15 '24
Buy
1.03
25,000
25,750
353,346
$20.90
price up icon 1.36%
$69.80
price up icon 0.31%
$32.42
price down icon 0.60%
$24.00
price up icon 0.25%
$103.85
price down icon 0.51%
biotechnology ONC
$249.09
price down icon 0.47%
Capitalizzazione:     |  Volume (24 ore):